• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • DMF (Drug Master Filing) – Pharmaceutical Products
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • CML (China Manufacture Licence) – Pressure vessels
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Company Profile
    • Partners
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Information
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • DMF
      • CCC
      • Pressure Vessels
    • Publications
    • Brochure
    • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • China Implements Trial Version of Real-World Data Guidelines

China Implements Trial Version of Real-World Data Guidelines

Friday, 18 December 2020 / Published in Medical Device, News, NMPA Registration in China

China Implements Trial Version of Real-World Data Guidelines

On November 26, 2020, the National Medical Products Administration (NMPA) issued technical guidelines (trial) for utilizing Real-World Data (RWD) in the medical device clinical evaluation process (No.77 – 2020). 

The document covers the following 5 major topics:

  1. The definition of RWD and real-world evidence (RWE)
  2. The advantages and limitations of real-world studies (RWS)
  3. Common sources and quality evaluation of the RWD
  4. Common types of RWS designs and methods for statistical data analysis
  5. Common situations where RWD can be applied in the clinical evaluation process

In the guidelines, the NMPA further addressed 11 common situations, summarised below, where RWD is justified for the clinical evaluation of medical devices:

  1. Provide clinical evidence for the clinical evaluation report (CER)
  2. Utilize the collected RWE for the product registration
  3. Utilize the collected RWE for the registration of urgently needed medical devices that had previously been approved only temporarily
  4. Utilize RWE collected from historical data of comparable patient cases as an external control for single-arm trials
  5. Serve as data reference for setting performance targets in single-arm trials
  6. Utilize the collected RWD to update the scope of application, indications, and contraindications
  7. Support the modification of the clinical claim indicated in the instructions for use (IFU/user manual)
  8. Support post-marketing research for medical devices with conditional approval
  9. Support long-term safety and efficacy evaluation for high-risk implantable medical devices
  10. Utilized in the full life-cycle clinical evaluation of medical devices for the treatment of patients with rare diseases with shortened time to market
  11. Support post-market surveillance

At this stage, the RWD can only serve as supplementary information and cannot yet fully replace the existing clinical evaluation paths, such as clinical trial in China, clinical evaluation of overseas clinical trial data, CER based on predicate device.

This legislation represents a further step towards other global leading regulatory frameworks.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: CER, Clinical Evaluation, Clinical Trials, Medical Devices, Real-world data, Real-world evidence

What you can read next

China SAMR 3 Stipulation Scheme Unveiled
Health Food Raw Materials and Functions
Simplification measures for CML (China Manufacturer License) as of March and June 2019

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Drug Master Filing
      • Health Food
      • Medical Device
    • RoHS
  • NMPA Registrierung in China
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • Administrative Measure on Cosmetics Registration and Filing

    On January 12, 2021, the State Administration f...
  • Cisema Webinar Series: NMPA Registration of Medical Devices in China

    We are delighted to announce that Cisema will b...
  • Webinar: DIT Life Sciences and Healthcare: How to register your medical device in China

    Date: February 18, 2021 Time: 9:00-10:00 GMT Re...
  • Cisema Partners with LifeSciences BC

    Cisema is delighted to announce a new partnersh...
  • China Regulatory Round-up for Health Food from November 2020 to January 2021

    On November 11, 2020, the Department of Food Sa...

Archive

Cisema

With nine locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Events
  • News & Information
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2019 Cisema. All rights reserved.

TOP